| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Benefit of radiation boost after whole-breast radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.40
|
|
2
|
Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. II. The case of T2N0 disease.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.04
|
|
3
|
Accelerated partial breast irradiation with IMRT: new technical approach and interim analysis of acute toxicity in a phase III randomized clinical trial.
|
Int J Radiat Oncol Biol Phys
|
2009
|
1.04
|
|
4
|
Association between single nucleotide polymorphisms in the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer.
|
Radiother Oncol
|
2011
|
1.04
|
|
5
|
Radiotherapy timing in 4,820 patients with breast cancer: university of florence experience.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.02
|
|
6
|
Swallowing dysfunction in head and neck cancer patients treated by radiotherapy: review and recommendations of the supportive task group of the Italian Association of Radiation Oncology.
|
Cancer Treat Rev
|
2012
|
0.97
|
|
7
|
Radical radiotherapy for early glottic cancer: Results in a series of 1087 patients from two Italian radiation oncology centers. I. The case of T1N0 disease.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.93
|
|
8
|
Late treatment-related complications in 214 patients with extremity soft-tissue sarcoma treated by surgery and postoperative radiation therapy.
|
Am J Surg
|
2006
|
0.90
|
|
9
|
Circulating tumour cells in locally advanced head and neck cancer: preliminary report about their possible role in predicting response to non-surgical treatment and survival.
|
Eur J Cancer
|
2012
|
0.89
|
|
10
|
Prognostic factors and clinical features in patients with leptominengeal metastases from breast cancer: a single center experience.
|
J Chemother
|
2012
|
0.87
|
|
11
|
Survival and breast relapse in 3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant treatment.
|
Radiother Oncol
|
2006
|
0.87
|
|
12
|
Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer: implications for supraclavicular nodal irradiation.
|
Int J Radiat Oncol Biol Phys
|
2009
|
0.87
|
|
13
|
Simultaneous integrated boost-intensity-modulated radiotherapy in head and neck cancer.
|
Laryngoscope
|
2013
|
0.86
|
|
14
|
Breast cancer in the elderly: treatment of 1500 patients.
|
Breast J
|
2006
|
0.86
|
|
15
|
Accelerated intensity-modulated external radiotherapy as a new technical approach to treat the index quadrant after conserving surgery in early breast cancer: a preliminary study.
|
Tumori
|
2005
|
0.84
|
|
16
|
Loco regional failure pattern after lumpectomy and breast irradiation in 4,185 patients with T1 and T2 breast cancer. Implications for nodal irradiation.
|
Acta Oncol
|
2006
|
0.83
|
|
17
|
Surgical options in radiotherapy-failed early glottic cancer.
|
Eur Arch Otorhinolaryngol
|
2013
|
0.82
|
|
18
|
Surface imaging, portal imaging, and skin marker set-up vs. CBCT for radiotherapy of the thorax and pelvis.
|
Strahlenther Onkol
|
2015
|
0.81
|
|
19
|
Low prevalence of K-RAS, EGF-R and BRAF mutations in sinonasal adenocarcinomas. Implications for anti-EGFR treatments.
|
Pathol Oncol Res
|
2013
|
0.81
|
|
20
|
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for early breast carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2008
|
0.80
|
|
21
|
Predictors of quality of life after radical treatment for prostate cancer.
|
Urol Int
|
2008
|
0.79
|
|
22
|
From a waiting list to a priority list: a computerized model for an easy-to-manage and automatically updated priority list in the booking of patients waiting for radiotherapy.
|
Tumori
|
2012
|
0.78
|
|
23
|
Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience.
|
Radiol Med
|
2013
|
0.78
|
|
24
|
Patterns of postoperative radiotherapy for head and neck cancer in Italy: a prospective, observational study by the head and neck group of the Italian Association for Radiation Oncology (AIRO).
|
Tumori
|
2011
|
0.78
|
|
25
|
Localized prostate cancer treated with intensity-modulated radiotherapy.
|
Tumori
|
2006
|
0.78
|
|
26
|
Accuracy of a 3D laser∕camera surface imaging system for setup verification of the pelvic and thoracic regions in radiotherapy treatments.
|
Med Phys
|
2013
|
0.78
|
|
27
|
Neoadjuvant treatment of soft tissue sarcoma.
|
Radiol Med
|
2013
|
0.77
|
|
28
|
Stereotactic body radiotherapy with CyberKnife for cardiac malignancies.
|
Tumori
|
2015
|
0.77
|
|
29
|
Salvage stereotactic re-irradiation with CyberKnife for locally recurrent head and neck cancer: a single center experience.
|
Tumori
|
2014
|
0.77
|
|
30
|
Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic breast cancer: single-center experience.
|
Med Oncol
|
2013
|
0.77
|
|
31
|
Clinical outcome of stereotactic body radiotherapy for abdominal lymph node metastases.
|
Tumori
|
2013
|
0.77
|
|
32
|
Reirradiation in head and neck recurrent or second primary tumor: efficacy, safety, and prognostic factors.
|
Tumori
|
2015
|
0.76
|
|
33
|
Alternating intravenous and oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of locally advanced breast cancer.
|
Anticancer Drugs
|
2006
|
0.75
|
|
34
|
Treatment of uterine sarcoma at the University of Florence from 1980-2001.
|
Tumori
|
2005
|
0.75
|
|
35
|
Application of helical tomotherapy for the treatment of a right atrium angiosarcoma: a case report.
|
Tumori
|
2013
|
0.75
|
|
36
|
Adjuvant Radiotherapy in High-Risk Squamous Cell Carcinoma of the Vulva: A Two-Institutional Italian Experience.
|
Oncol Res Treat
|
2017
|
0.75
|
|
37
|
Clinical Outcomes of Stereotactic Body Radiotherapy in Oligometastatic Gynecological Cancer.
|
Int J Gynecol Cancer
|
2017
|
0.75
|
|
38
|
Definitive Radiotherapy for Primary Squamous Cell Carcinoma of the Vagina: Are High-Dose External Beam Radiotherapy and High-Dose-Rate Brachytherapy Boost the Best Treatment Experience of Two Italian Institutes.
|
Oncol Res Treat
|
2017
|
0.75
|